Review



non adherent pc12 cells  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 98
      Buy from Supplier

    Structured Review

    ATCC non adherent pc12 cells
    Optimisation of media for 3 <t>PC12</t> cell variants. Cells were adapted from their original media as described in “ ”. Representative phase contrast images are shown after 3 passages in the new media and imaged 2–3 days after passaging. All cells were supplemented with 15% horse serum and 2.5% foetal bovine serum. ( A ) PC12 Adh cells were adapted from Ham’s F-12K to DMEM and RPMI, with no differences seen in cell morphology. ( B ) PC12 cells Riken were adapted from DMEM to RPMI resulting in rounded, phase-bright cells with loss of cell-substratum adhesion. ( C ) NS-1 cells adapted from RPMI to DMEM showed increased neurite outgrowth. Scale bar ( A ) 200 µm. ( B , C ) 100 µm.
    Non Adherent Pc12 Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 98/100, based on 4345 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/non+adherent+pc12+cells/pmc08046774-181-0-5?v=ATCC
    Average 98 stars, based on 4345 article reviews
    non adherent pc12 cells - by Bioz Stars, 2026-07
    98/100 stars

    Images

    1) Product Images from "Optimisation of a PC12 cell-based in vitro stroke model for screening neuroprotective agents"

    Article Title: Optimisation of a PC12 cell-based in vitro stroke model for screening neuroprotective agents

    Journal: Scientific Reports

    doi: 10.1038/s41598-021-87431-4

    Optimisation of media for 3 PC12 cell variants. Cells were adapted from their original media as described in “ ”. Representative phase contrast images are shown after 3 passages in the new media and imaged 2–3 days after passaging. All cells were supplemented with 15% horse serum and 2.5% foetal bovine serum. ( A ) PC12 Adh cells were adapted from Ham’s F-12K to DMEM and RPMI, with no differences seen in cell morphology. ( B ) PC12 cells Riken were adapted from DMEM to RPMI resulting in rounded, phase-bright cells with loss of cell-substratum adhesion. ( C ) NS-1 cells adapted from RPMI to DMEM showed increased neurite outgrowth. Scale bar ( A ) 200 µm. ( B , C ) 100 µm.
    Figure Legend Snippet: Optimisation of media for 3 PC12 cell variants. Cells were adapted from their original media as described in “ ”. Representative phase contrast images are shown after 3 passages in the new media and imaged 2–3 days after passaging. All cells were supplemented with 15% horse serum and 2.5% foetal bovine serum. ( A ) PC12 Adh cells were adapted from Ham’s F-12K to DMEM and RPMI, with no differences seen in cell morphology. ( B ) PC12 cells Riken were adapted from DMEM to RPMI resulting in rounded, phase-bright cells with loss of cell-substratum adhesion. ( C ) NS-1 cells adapted from RPMI to DMEM showed increased neurite outgrowth. Scale bar ( A ) 200 µm. ( B , C ) 100 µm.

    Techniques Used: Passaging

    Optimisation of substratum coating for 3 PC12 variants. PC12 cells were cultured in media with 15% horse serum and 2.5% foetal bovine serum ( A , C , E ) or serum-free supplemented media ( B , D ) as described in “ ”. Cells were passaged into 6-well plates with the wells either uncoated (non) or coated with collagen I (I), collagen IV (IV), poly- d -lysine (PDL), poly- l -lysine (PLL) or laminin (LM). Representative phase contrast photomicrographs were imaged after 24 h. ( A , B ) PC12 Adh cells cultured in Ham’s F-12 K medium were passaged into a 6-well plate with the indicated substratum coating with serum ( A ) or without serum ( B ). ( C , D ) PC12 Riken cells cultured in DMEM medium were passaged into wells with the indicated substratum coatings with serum ( C ) or without serum ( D ). ( E ) NS-1 cells cultured in DMEM medium with serum were passaged into a 6-well plate having substrata with the indicated coatings. Scale bar ( A , B ) 200 µm. ( C – E ) 100 µm.
    Figure Legend Snippet: Optimisation of substratum coating for 3 PC12 variants. PC12 cells were cultured in media with 15% horse serum and 2.5% foetal bovine serum ( A , C , E ) or serum-free supplemented media ( B , D ) as described in “ ”. Cells were passaged into 6-well plates with the wells either uncoated (non) or coated with collagen I (I), collagen IV (IV), poly- d -lysine (PDL), poly- l -lysine (PLL) or laminin (LM). Representative phase contrast photomicrographs were imaged after 24 h. ( A , B ) PC12 Adh cells cultured in Ham’s F-12 K medium were passaged into a 6-well plate with the indicated substratum coating with serum ( A ) or without serum ( B ). ( C , D ) PC12 Riken cells cultured in DMEM medium were passaged into wells with the indicated substratum coatings with serum ( C ) or without serum ( D ). ( E ) NS-1 cells cultured in DMEM medium with serum were passaged into a 6-well plate having substrata with the indicated coatings. Scale bar ( A , B ) 200 µm. ( C – E ) 100 µm.

    Techniques Used: Cell Culture

    NGF differentiation of 3 PC12 cell variants. PC12 cells were cultured as described in “ ” and seeded into multiwell plates. After an overnight incubation, the media was changed to one with 2% horse serum (1% for PC12 Adh) and NGF added to the indicated concentration (ng/ml). The media and NGF was refreshed every 48 h and neurite scoring performed at 96 h. ( A ) PC12 Adh cells cultured in Ham’s F-12 K with serum were seeded into a poly- d -lysine-coated 6-well plate at 3 × 10 3 cells/cm 2 . Representative phase contrast images at 100 × magnification were taken 96 h after addition of the indicated concentration of NGF (ng/ml). ( B ) PC12 Riken cells cultured in DMEM with serum were plated onto a 12-well plate coated with collagen IV at a density of 4 × 10 3 cells/cm 2 . Representative phase contrast images at 200X magnification are shown 96 h after addition of NGF at the indicated concentrations (ng/ml). ( C ) NS-1 cells cultured in DMEM with serum were seeded into a collagen-IV coated 12-well plate at a density of 4 × 10 3 cells/cm 2 . Representative phase contrast images (200X magnification) are shown 96 h after addition of NGF at the indicated concentration (ng/ml). ( D ) Three PC12 variants were treated with NGF at the indicated concentrations and the percentage of neurite-bearing cells obtained after 96 h. Data shown is the mean and ± SEM of 3 independent experiments. Scale bar ( A ) 200 µm, ( B , C ) 100 µm.
    Figure Legend Snippet: NGF differentiation of 3 PC12 cell variants. PC12 cells were cultured as described in “ ” and seeded into multiwell plates. After an overnight incubation, the media was changed to one with 2% horse serum (1% for PC12 Adh) and NGF added to the indicated concentration (ng/ml). The media and NGF was refreshed every 48 h and neurite scoring performed at 96 h. ( A ) PC12 Adh cells cultured in Ham’s F-12 K with serum were seeded into a poly- d -lysine-coated 6-well plate at 3 × 10 3 cells/cm 2 . Representative phase contrast images at 100 × magnification were taken 96 h after addition of the indicated concentration of NGF (ng/ml). ( B ) PC12 Riken cells cultured in DMEM with serum were plated onto a 12-well plate coated with collagen IV at a density of 4 × 10 3 cells/cm 2 . Representative phase contrast images at 200X magnification are shown 96 h after addition of NGF at the indicated concentrations (ng/ml). ( C ) NS-1 cells cultured in DMEM with serum were seeded into a collagen-IV coated 12-well plate at a density of 4 × 10 3 cells/cm 2 . Representative phase contrast images (200X magnification) are shown 96 h after addition of NGF at the indicated concentration (ng/ml). ( D ) Three PC12 variants were treated with NGF at the indicated concentrations and the percentage of neurite-bearing cells obtained after 96 h. Data shown is the mean and ± SEM of 3 independent experiments. Scale bar ( A ) 200 µm, ( B , C ) 100 µm.

    Techniques Used: Cell Culture, Incubation, Concentration Assay

    Optimisation and validation of PC12 NS-1 in vitro stroke model. ( A ) NGF-differentiated NS-1 cells were subjected to OGD as described under “ ”. Caspase 3/7 activity was measured at the indicated durations of OGD and data normalised as fold increase over cells without OGD. Data shown is mean ± SEM from 3 independent experiments of triplicate determination. Statistical testing was performed with one-way ANOVA with Dunnett’s post hoc test. ***p < 0.001 compared to non-OGD control ( B ) NS-1 cells differentiated with NGF were subjected to OGD as described under “ ” for the indicated durations. Cell viability was then assessed using the MTT assay and data normalised to control cells without OGD. Data are mean ± SEM of 3 independent experiments carried out in triplicate. ***p < 0.001 compared to non-OGD control. Differentiated NS-1 cells were subjected to 3 h OGD then 24 h of normal culture conditions added with WAY100635 or 8-OH-DPAT (or both) as described under “ ”. Subsequently, cell viability or apoptosis was measured. ( C ) Cell viability was determined with MTT assay. *p < 0.05 compared to non-OGD control. ( D ) Caspase 3/7 activity was measured. Non-OGD baseline activity was removed and data normalised to untreated cells. **p < 0.01 compared to untreated control. All data are expressed as mean ± SEM of 3 experiments determined in triplicate.
    Figure Legend Snippet: Optimisation and validation of PC12 NS-1 in vitro stroke model. ( A ) NGF-differentiated NS-1 cells were subjected to OGD as described under “ ”. Caspase 3/7 activity was measured at the indicated durations of OGD and data normalised as fold increase over cells without OGD. Data shown is mean ± SEM from 3 independent experiments of triplicate determination. Statistical testing was performed with one-way ANOVA with Dunnett’s post hoc test. ***p < 0.001 compared to non-OGD control ( B ) NS-1 cells differentiated with NGF were subjected to OGD as described under “ ” for the indicated durations. Cell viability was then assessed using the MTT assay and data normalised to control cells without OGD. Data are mean ± SEM of 3 independent experiments carried out in triplicate. ***p < 0.001 compared to non-OGD control. Differentiated NS-1 cells were subjected to 3 h OGD then 24 h of normal culture conditions added with WAY100635 or 8-OH-DPAT (or both) as described under “ ”. Subsequently, cell viability or apoptosis was measured. ( C ) Cell viability was determined with MTT assay. *p < 0.05 compared to non-OGD control. ( D ) Caspase 3/7 activity was measured. Non-OGD baseline activity was removed and data normalised to untreated cells. **p < 0.01 compared to untreated control. All data are expressed as mean ± SEM of 3 experiments determined in triplicate.

    Techniques Used: Biomarker Discovery, In Vitro, Activity Assay, Control, MTT Assay

    Application of PC12 NS-1 in vitro stroke model. ( A ) After 3-h OGD, NGF-differentiated NS-1 cells were incubated at normal conditions and treated with the indicated drugs as described under “ ”. Cell viability was determined by MTT assay. Data was normalised to untreated control cells. ( B ) Differentiated, non-OGD PC12 NS-1 cells were treated with the indicated drugs as described under “ ”. Cell viability was measured with MTT assay. Data was normalised to untreated control. ( C ) NGF-differentiated NS-1 cells were subjected to 3-h OGD followed by 24 h incubation at normal conditions with the indicated drugs as described under “ ”. Caspase 3/7 activity was measured. Non-OGD baseline activity was removed and data normalised to untreated cells. *p < 0.05 compared to control untreated cells; **p < 0.01 compared to control untreated cells. All data are expressed as mean ± SEM of 3 experiments determined in triplicate.
    Figure Legend Snippet: Application of PC12 NS-1 in vitro stroke model. ( A ) After 3-h OGD, NGF-differentiated NS-1 cells were incubated at normal conditions and treated with the indicated drugs as described under “ ”. Cell viability was determined by MTT assay. Data was normalised to untreated control cells. ( B ) Differentiated, non-OGD PC12 NS-1 cells were treated with the indicated drugs as described under “ ”. Cell viability was measured with MTT assay. Data was normalised to untreated control. ( C ) NGF-differentiated NS-1 cells were subjected to 3-h OGD followed by 24 h incubation at normal conditions with the indicated drugs as described under “ ”. Caspase 3/7 activity was measured. Non-OGD baseline activity was removed and data normalised to untreated cells. *p < 0.05 compared to control untreated cells; **p < 0.01 compared to control untreated cells. All data are expressed as mean ± SEM of 3 experiments determined in triplicate.

    Techniques Used: In Vitro, Incubation, MTT Assay, Control, Activity Assay



    Similar Products

    non adherent pc12 cells  (ATCC)
    98
    ATCC non adherent pc12 cells
    Optimisation of media for 3 <t>PC12</t> cell variants. Cells were adapted from their original media as described in “ ”. Representative phase contrast images are shown after 3 passages in the new media and imaged 2–3 days after passaging. All cells were supplemented with 15% horse serum and 2.5% foetal bovine serum. ( A ) PC12 Adh cells were adapted from Ham’s F-12K to DMEM and RPMI, with no differences seen in cell morphology. ( B ) PC12 cells Riken were adapted from DMEM to RPMI resulting in rounded, phase-bright cells with loss of cell-substratum adhesion. ( C ) NS-1 cells adapted from RPMI to DMEM showed increased neurite outgrowth. Scale bar ( A ) 200 µm. ( B , C ) 100 µm.
    Non Adherent Pc12 Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/non+adherent+pc12+cells/pmc08046774-181-0-5?v=ATCC
    Average 98 stars, based on 1 article reviews
    non adherent pc12 cells - by Bioz Stars, 2026-07
    98/100 stars
    		  Buy from Supplier

    Image Search Results


    Optimisation of media for 3 PC12 cell variants. Cells were adapted from their original media as described in “ ”. Representative phase contrast images are shown after 3 passages in the new media and imaged 2–3 days after passaging. All cells were supplemented with 15% horse serum and 2.5% foetal bovine serum. ( A ) PC12 Adh cells were adapted from Ham’s F-12K to DMEM and RPMI, with no differences seen in cell morphology. ( B ) PC12 cells Riken were adapted from DMEM to RPMI resulting in rounded, phase-bright cells with loss of cell-substratum adhesion. ( C ) NS-1 cells adapted from RPMI to DMEM showed increased neurite outgrowth. Scale bar ( A ) 200 µm. ( B , C ) 100 µm.

    Journal: Scientific Reports

    Article Title: Optimisation of a PC12 cell-based in vitro stroke model for screening neuroprotective agents

    doi: 10.1038/s41598-021-87431-4

    Figure Lengend Snippet: Optimisation of media for 3 PC12 cell variants. Cells were adapted from their original media as described in “ ”. Representative phase contrast images are shown after 3 passages in the new media and imaged 2–3 days after passaging. All cells were supplemented with 15% horse serum and 2.5% foetal bovine serum. ( A ) PC12 Adh cells were adapted from Ham’s F-12K to DMEM and RPMI, with no differences seen in cell morphology. ( B ) PC12 cells Riken were adapted from DMEM to RPMI resulting in rounded, phase-bright cells with loss of cell-substratum adhesion. ( C ) NS-1 cells adapted from RPMI to DMEM showed increased neurite outgrowth. Scale bar ( A ) 200 µm. ( B , C ) 100 µm.

    Article Snippet: Non-adherent PC12 cells (CRL-1721) from ATCC had been previously studied , , .

    Techniques: Passaging

    Optimisation of substratum coating for 3 PC12 variants. PC12 cells were cultured in media with 15% horse serum and 2.5% foetal bovine serum ( A , C , E ) or serum-free supplemented media ( B , D ) as described in “ ”. Cells were passaged into 6-well plates with the wells either uncoated (non) or coated with collagen I (I), collagen IV (IV), poly- d -lysine (PDL), poly- l -lysine (PLL) or laminin (LM). Representative phase contrast photomicrographs were imaged after 24 h. ( A , B ) PC12 Adh cells cultured in Ham’s F-12 K medium were passaged into a 6-well plate with the indicated substratum coating with serum ( A ) or without serum ( B ). ( C , D ) PC12 Riken cells cultured in DMEM medium were passaged into wells with the indicated substratum coatings with serum ( C ) or without serum ( D ). ( E ) NS-1 cells cultured in DMEM medium with serum were passaged into a 6-well plate having substrata with the indicated coatings. Scale bar ( A , B ) 200 µm. ( C – E ) 100 µm.

    Journal: Scientific Reports

    Article Title: Optimisation of a PC12 cell-based in vitro stroke model for screening neuroprotective agents

    doi: 10.1038/s41598-021-87431-4

    Figure Lengend Snippet: Optimisation of substratum coating for 3 PC12 variants. PC12 cells were cultured in media with 15% horse serum and 2.5% foetal bovine serum ( A , C , E ) or serum-free supplemented media ( B , D ) as described in “ ”. Cells were passaged into 6-well plates with the wells either uncoated (non) or coated with collagen I (I), collagen IV (IV), poly- d -lysine (PDL), poly- l -lysine (PLL) or laminin (LM). Representative phase contrast photomicrographs were imaged after 24 h. ( A , B ) PC12 Adh cells cultured in Ham’s F-12 K medium were passaged into a 6-well plate with the indicated substratum coating with serum ( A ) or without serum ( B ). ( C , D ) PC12 Riken cells cultured in DMEM medium were passaged into wells with the indicated substratum coatings with serum ( C ) or without serum ( D ). ( E ) NS-1 cells cultured in DMEM medium with serum were passaged into a 6-well plate having substrata with the indicated coatings. Scale bar ( A , B ) 200 µm. ( C – E ) 100 µm.

    Article Snippet: Non-adherent PC12 cells (CRL-1721) from ATCC had been previously studied , , .

    Techniques: Cell Culture

    NGF differentiation of 3 PC12 cell variants. PC12 cells were cultured as described in “ ” and seeded into multiwell plates. After an overnight incubation, the media was changed to one with 2% horse serum (1% for PC12 Adh) and NGF added to the indicated concentration (ng/ml). The media and NGF was refreshed every 48 h and neurite scoring performed at 96 h. ( A ) PC12 Adh cells cultured in Ham’s F-12 K with serum were seeded into a poly- d -lysine-coated 6-well plate at 3 × 10 3 cells/cm 2 . Representative phase contrast images at 100 × magnification were taken 96 h after addition of the indicated concentration of NGF (ng/ml). ( B ) PC12 Riken cells cultured in DMEM with serum were plated onto a 12-well plate coated with collagen IV at a density of 4 × 10 3 cells/cm 2 . Representative phase contrast images at 200X magnification are shown 96 h after addition of NGF at the indicated concentrations (ng/ml). ( C ) NS-1 cells cultured in DMEM with serum were seeded into a collagen-IV coated 12-well plate at a density of 4 × 10 3 cells/cm 2 . Representative phase contrast images (200X magnification) are shown 96 h after addition of NGF at the indicated concentration (ng/ml). ( D ) Three PC12 variants were treated with NGF at the indicated concentrations and the percentage of neurite-bearing cells obtained after 96 h. Data shown is the mean and ± SEM of 3 independent experiments. Scale bar ( A ) 200 µm, ( B , C ) 100 µm.

    Journal: Scientific Reports

    Article Title: Optimisation of a PC12 cell-based in vitro stroke model for screening neuroprotective agents

    doi: 10.1038/s41598-021-87431-4

    Figure Lengend Snippet: NGF differentiation of 3 PC12 cell variants. PC12 cells were cultured as described in “ ” and seeded into multiwell plates. After an overnight incubation, the media was changed to one with 2% horse serum (1% for PC12 Adh) and NGF added to the indicated concentration (ng/ml). The media and NGF was refreshed every 48 h and neurite scoring performed at 96 h. ( A ) PC12 Adh cells cultured in Ham’s F-12 K with serum were seeded into a poly- d -lysine-coated 6-well plate at 3 × 10 3 cells/cm 2 . Representative phase contrast images at 100 × magnification were taken 96 h after addition of the indicated concentration of NGF (ng/ml). ( B ) PC12 Riken cells cultured in DMEM with serum were plated onto a 12-well plate coated with collagen IV at a density of 4 × 10 3 cells/cm 2 . Representative phase contrast images at 200X magnification are shown 96 h after addition of NGF at the indicated concentrations (ng/ml). ( C ) NS-1 cells cultured in DMEM with serum were seeded into a collagen-IV coated 12-well plate at a density of 4 × 10 3 cells/cm 2 . Representative phase contrast images (200X magnification) are shown 96 h after addition of NGF at the indicated concentration (ng/ml). ( D ) Three PC12 variants were treated with NGF at the indicated concentrations and the percentage of neurite-bearing cells obtained after 96 h. Data shown is the mean and ± SEM of 3 independent experiments. Scale bar ( A ) 200 µm, ( B , C ) 100 µm.

    Article Snippet: Non-adherent PC12 cells (CRL-1721) from ATCC had been previously studied , , .

    Techniques: Cell Culture, Incubation, Concentration Assay

    Optimisation and validation of PC12 NS-1 in vitro stroke model. ( A ) NGF-differentiated NS-1 cells were subjected to OGD as described under “ ”. Caspase 3/7 activity was measured at the indicated durations of OGD and data normalised as fold increase over cells without OGD. Data shown is mean ± SEM from 3 independent experiments of triplicate determination. Statistical testing was performed with one-way ANOVA with Dunnett’s post hoc test. ***p < 0.001 compared to non-OGD control ( B ) NS-1 cells differentiated with NGF were subjected to OGD as described under “ ” for the indicated durations. Cell viability was then assessed using the MTT assay and data normalised to control cells without OGD. Data are mean ± SEM of 3 independent experiments carried out in triplicate. ***p < 0.001 compared to non-OGD control. Differentiated NS-1 cells were subjected to 3 h OGD then 24 h of normal culture conditions added with WAY100635 or 8-OH-DPAT (or both) as described under “ ”. Subsequently, cell viability or apoptosis was measured. ( C ) Cell viability was determined with MTT assay. *p < 0.05 compared to non-OGD control. ( D ) Caspase 3/7 activity was measured. Non-OGD baseline activity was removed and data normalised to untreated cells. **p < 0.01 compared to untreated control. All data are expressed as mean ± SEM of 3 experiments determined in triplicate.

    Journal: Scientific Reports

    Article Title: Optimisation of a PC12 cell-based in vitro stroke model for screening neuroprotective agents

    doi: 10.1038/s41598-021-87431-4

    Figure Lengend Snippet: Optimisation and validation of PC12 NS-1 in vitro stroke model. ( A ) NGF-differentiated NS-1 cells were subjected to OGD as described under “ ”. Caspase 3/7 activity was measured at the indicated durations of OGD and data normalised as fold increase over cells without OGD. Data shown is mean ± SEM from 3 independent experiments of triplicate determination. Statistical testing was performed with one-way ANOVA with Dunnett’s post hoc test. ***p < 0.001 compared to non-OGD control ( B ) NS-1 cells differentiated with NGF were subjected to OGD as described under “ ” for the indicated durations. Cell viability was then assessed using the MTT assay and data normalised to control cells without OGD. Data are mean ± SEM of 3 independent experiments carried out in triplicate. ***p < 0.001 compared to non-OGD control. Differentiated NS-1 cells were subjected to 3 h OGD then 24 h of normal culture conditions added with WAY100635 or 8-OH-DPAT (or both) as described under “ ”. Subsequently, cell viability or apoptosis was measured. ( C ) Cell viability was determined with MTT assay. *p < 0.05 compared to non-OGD control. ( D ) Caspase 3/7 activity was measured. Non-OGD baseline activity was removed and data normalised to untreated cells. **p < 0.01 compared to untreated control. All data are expressed as mean ± SEM of 3 experiments determined in triplicate.

    Article Snippet: Non-adherent PC12 cells (CRL-1721) from ATCC had been previously studied , , .

    Techniques: Biomarker Discovery, In Vitro, Activity Assay, Control, MTT Assay

    Application of PC12 NS-1 in vitro stroke model. ( A ) After 3-h OGD, NGF-differentiated NS-1 cells were incubated at normal conditions and treated with the indicated drugs as described under “ ”. Cell viability was determined by MTT assay. Data was normalised to untreated control cells. ( B ) Differentiated, non-OGD PC12 NS-1 cells were treated with the indicated drugs as described under “ ”. Cell viability was measured with MTT assay. Data was normalised to untreated control. ( C ) NGF-differentiated NS-1 cells were subjected to 3-h OGD followed by 24 h incubation at normal conditions with the indicated drugs as described under “ ”. Caspase 3/7 activity was measured. Non-OGD baseline activity was removed and data normalised to untreated cells. *p < 0.05 compared to control untreated cells; **p < 0.01 compared to control untreated cells. All data are expressed as mean ± SEM of 3 experiments determined in triplicate.

    Journal: Scientific Reports

    Article Title: Optimisation of a PC12 cell-based in vitro stroke model for screening neuroprotective agents

    doi: 10.1038/s41598-021-87431-4

    Figure Lengend Snippet: Application of PC12 NS-1 in vitro stroke model. ( A ) After 3-h OGD, NGF-differentiated NS-1 cells were incubated at normal conditions and treated with the indicated drugs as described under “ ”. Cell viability was determined by MTT assay. Data was normalised to untreated control cells. ( B ) Differentiated, non-OGD PC12 NS-1 cells were treated with the indicated drugs as described under “ ”. Cell viability was measured with MTT assay. Data was normalised to untreated control. ( C ) NGF-differentiated NS-1 cells were subjected to 3-h OGD followed by 24 h incubation at normal conditions with the indicated drugs as described under “ ”. Caspase 3/7 activity was measured. Non-OGD baseline activity was removed and data normalised to untreated cells. *p < 0.05 compared to control untreated cells; **p < 0.01 compared to control untreated cells. All data are expressed as mean ± SEM of 3 experiments determined in triplicate.

    Article Snippet: Non-adherent PC12 cells (CRL-1721) from ATCC had been previously studied , , .

    Techniques: In Vitro, Incubation, MTT Assay, Control, Activity Assay